



Better Health, Brighter Future

February 2nd, 2024

Dear Colleagues/Customers,

Takeda Canada would like to inform you about a statement added to the Warnings & Precautions section of GAMMAGARD[®] S/D Product Monograph.

GAMMAGARD[®] S/D

As of May 2023, a new statement was added to the Dosage and Administration section of the GAMMAGARD[®] S/D Product Monograph. The new statement can be read as follows: *“For patients at risk for measles exposure: If a patient has been exposed to measles, please refer to the National Advisory Committee on Immunization (NACI) recommendations for measles post-exposure prophylaxis.”*

To ensure safe use of the GAMMAGARD[®] S/D product, please refer to the prescribing information contained within the current GAMMAGARD[®] S/D Product Monograph, available in English and French at <https://takeda.info/en-ca-gammagard-sdpm> and <https://takeda.info/fr-ca-gammagard-sdmp>. If additional information is required please contact Medical Information at 1.800.268.2772 or medinfoCA@takeda.com.

In case of any adverse event suspected, the details and the Medical Information contact details can be found online at <https://www.takeda.com/en-ca/what-we-do/our-medicines>

Suspected side effects can also be directly reported by email to AE.CAN@takeda.com.

To report adverse event or side effects to Health Canada, please complete the form online via <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html> or by calling toll-free at 1-866-234-2345.

Sincerely,

Jefferson Tea, PhD, MBA
Vice President/Head of Medical & Scientific Affairs
Takeda Canada Inc.
22 Adelaide Street West, suite 3800
Toronto, ON M5H 4E3, Canada
Telephone: 1.647.798.2200 or 1.866.397.4473
<https://www.takeda.com/en-ca>